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Abstract
With limited autologous and donor bone graft availability, there is an increasing need for alternative graft 
substitutes. We have previously shown that chondrogenically priming mesenchymal stem cell (MSC) pellets 
for 28 d in vitro will reproducibly result in endochondral bone formation after in vivo implantation. However, 
pellet priming time for clinical applications is quite extensive. A micropellet (μpellet)-fibrin construct was 
developed and coupled, with a shorter priming period, determined by an in vitro time course experiment. 
In vitro data showed expression of chondrogenic genes and matrix production after 7 d of chondrogenic 
priming, indicating that briefer priming could possibly be used to induce bone formation in vivo. 7 and 28 d 
primed pellet, pellet-fibrin and μpellet-fibrin constructs were cultured for in vitro analysis and implanted 
subcutaneously for 8 weeks into nude mice. μpellet-fibrin constructs, cultured in vitro for 7 or 28 d, produced 
comparable bone to standard pellets in vivo. MSC-mediated bone formation was achieved following only 
7 d of in vitro priming. Bone formation in vivo appeared to be influenced by overall matrix production 
pre-implantation. Given this short priming time and the injectable nature of the μpellet-fibrin constructs, 
this approach might be further developed as an injectable bone substitute, leading to a minimally-invasive 
treatment option, which would allow for tailored filling of bone defects.
Keywords: Bone tissue engineering, endochondral ossification, fibrin, mesenchymal stem cells, hydrogel, 
bone, micropellet, chondrogenesis, marrow, injectable.
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Introduction
Availability of autologous graft material for 
reconstruction of large bone defects is limited and, 
as harvesting is associated with additional patient 
risk and discomfort, there is an increasing need for 
suitable graft alternatives (Amini et al., 2012; Damien 
and Parsons, 1991; Gawlitta et al., 2010).
 Developmental engineering, mimicking the 
processes of tissue development and healing, to create 
biologically-relevant replacements for congenitally 
missing, worn out or damaged tissues, is commonly 
implemented in bone tissue engineering to develop 
replacements for autologous grafts (Badylak, 2005; 
Dimitriou et al., 2005). Bone formation predominantly 
proceeds through two mechanisms: intramembranous 
(IO) and endochondral ossification (EO). With 
varying degrees of success, both mechanisms are 
exploited for bone graft development, using stem 
cells and other cell types (Bahney et al., 2014; Huang 
et al., 2006; Olsen et al., 2000; Tortelli et al., 2010). 
Although the IO route of bone formation is often 
used in tissue engineering (TE), grafts often exhibit 
poor survival due to insufficient vascularisation and 
perfusion following implantation (Sheehy et al., 2013). 
For these reasons, this work focused on achieving 
tissue engineered bone through the EO pathway.
 Endochondral bone formation relies on a 
cartilage intermediate (Bianco et al., 1998; Maes 
et al., 2010). Mesenchymal cells condense and 
undergo chondrogenic differentiation, leading to the 
production of a cartilage template rich in collagens, 
glycosaminoglycans (GAGs) and bioactive signalling 
molecules (Kronenberg, 2003; Ortega et al., 2004). 
As the process continues, the chondrogenic matrix 
is calcified and degraded, resulting in the release of 
these molecules (Nagai and Aoki, 2002; Ortega et al., 
2004; Street et al., 2002), which trigger cell migration, 
blood vessel invasion and ultimately bone formation 
(Boyan et al., 1992; Chen et al., 2012; Gawlitta et al., 2010; 
Gerber, 1999). It has previously been shown that EO 
can be mimicked in order to achieve bone formation 
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using chondrogenically primed mesenchymal 
stem cell (MSC) pellets (Farrell et al., 2011; van der 
Stok et al., 2014). Chondrogenically differentiated 
MSC pellets in vitro for 28 d result in vascularised, 
endochondral bone when subcutaneously implanted 
in vivo for 8 weeks. This approach to TE bone 
formation is advantageous, as cartilage is better 
suited to survive in the initial avascular environment 
and naturally promotes the revascularisation of 
the graft material when implanted into defect sites 
(Yang et al., 2014). Whilst a promising approach 
to bone regeneration, hurdles remain when trying 
to implement such techniques clinically. A major 
obstacle is the lengthy in vitro priming time required 
to differentiate pellets to stimulate endochondral 
ossification in vivo, a process which is essential as 
undifferentiated MSC pellets typically fail to form 
bone or form an insufficient quantity to heal defects 
(van der Stok et al., 2014). It has recently been shown 
that in vitro priming can be reduced to 14 d; however, 
it has not been investigated whether further reduction 
is possible, to allow for a swifter patient treatment 
(Yang et al., 2015). In vitro priming time is further 
compounded by the fact that inherent variation 
among MSC donors result in varying degrees of 
chondrogenic differentiation, which can affect 
the quantity and quality of bone produced in vivo 
(Osinga et al., 2016; Scotti et al., 2010; van der Stok et 
al., 2014). In order for these constructs to be clinically 
relevant, criteria for in vitro differentiation, which 
are shown to lead to reproducible bone formation, 
must be identified. However, in vitro priming and 
donor variation are not the only obstacles between 
these constructs and clinical translation. Isolation 
of MSCs from bone marrow requires a painful 
surgical procedure, always followed by a secondary 
surgical procedure – subsequent to the construction 
of the MSC pellets – required for the implantation 
of the graft. The development of an injectable bone 
substitute would allow for a less invasive treatment 
option and, possibly, decreased recovery time.
 To address these issues, we have created 
chondrogenically primed constructs comprised of 
micropellets (μpellets) suspended within a fibrin 
hydrogel. This approach exploits the reproducible 
and swift bone-forming capacity of MSC pellets, 
coupled with a shorter in vitro priming time to 
decrease the pre-implantation time. μpellet constructs 
are promising constructs since their small size 
allows them to pass easily through a hypodermic 
needle, making them ideal for an injectable therapy. 
This would allow clinicians to properly fill a defect 
site without the need for a tailor-printed/designed 
implant to fit specific void shapes and it would 
result in decreased patient discomfort and possibly 
recovery time.
 In this study, we aimed to examine the bone-
forming potential of these μpellet constructs. We 
investigated decreased in vitro priming with the goal 
of achieving bone formation in a shorter time than 
the one so far reported. Additionally, we observed 
how differences in chondrogenic potential pre-
implantation influence endochondral bone formed 
in vivo.
Materials and Methods
MSC isolation
Human bone marrow MSCs were isolated from 3 
different consenting patients undergoing total hip 
arthroplasty [Medical Ethical Testing Commission 
(METC) approval code 2004-142; donor 1: female, 
60 years old; donor 2: male, 34 years old; donor 
3: male, 58 years old] and expanded in alpha 
modifications minimum essential medium (αMEM) 
containing 10 % foetal bovine serum (FBS) serum (lot 
#41Q204K, Gibco, Bleiswijk, The Netherlands) and 
supplemented with 50 μg/mL gentamycin, 1.5 μg/
mL fungizone, 25 μg/mL L-ascorbic acid 2-phosphate 
and 1 ng/mL fibroblast growth factor-2 (all from 
Instruchemie, Delfzijl, The Netherlands). Heparinised 
bone marrow aspirates were taken from the greater 
trochanter and plated at the concentration of 30-
100 × 106 nucleated cells per T175 flask (Corning, 
Amsterdam, The Netherlands). 24 h after plating, 
flasks were washed to remove non-adherent cells 
and debris and the medium was changed. Cells were 
cultured at 37 °C and 5 % carbon dioxide (CO2) and 
medium was changed twice a week. MSCs were 
passed once reached 85-90 % confluence using 0.05 % 
trypsin (Gibco) and replated at a concentration of 
approximately 2,800 cells/cm2. Cells were expanded 
to passage-4, at which time they had differentiated 
chondrogenically.
Chondrogenic differentiation
To create standard pellets, 2 × 105 MSCs were 
suspended in 15 mL polypropylene tubes in complete 
chondrogenic medium [high-glucose Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented 
with 50 μg/mL gentamycin (Invitrogen, Landsmeer, 
The Netherlands), 1.5 μg/mL fungizone (Invitrogen), 
1 mM sodium pyruvate (Invitrogen), 40 μg/mL proline 
(Sigma-Aldrich, Zwijndrecht, The Netherlands), 
1 : 100 v/v insulin-transferrin-selenium (ITS+; BD 
Biosciences, Temse, Beligum), 10 ng/mL transforming 
growth factor β3 (Peprotech, London, UK), 25 μg/
mL L-ascorbic acid 2-phosphate (Sigma-Aldrich) 
and 100 nM dexamethasone (Sigma-Aldrich)] and 
centrifuged for 8 min at 200 ×g. To generate μpellets, 
3 × 106 MSCs per well were seeded in AggreWell™800 
plates (STEMCELL Technologies, Evergem, Belgium) 
in 1 mL chondrogenic medium, centrifuged at 300 ×g 
for 10 min and incubated overnight creating 300 
μpellets (10,000 cells per μpellet) per well. Following 
24 h of incubation, μpellets were transferred to 24 well 
plates (Corning, Zwijndrecht, The Netherlands) or 
fibrin encapsulated. Cells undergoing chondrogenic 
differentiation were cultured at a ratio of 4 × 105 
cells/mL in complete chondrogenic medium. All 
conditions were cultured at 37 °C in 5 % CO2.
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Chondrogenic time course
M S C s ( d o n o r  i n f o r m a t i o n  a b o v e )  w e r e 
chondrogenically differentiated through standard 
pellet culture conditions, as described. For histological 
analysis, samples were harvested following 2, 5, 7, 10, 
14 and 28 d of differentiation. Samples were fixed for 
2 h in 4 % (w/v) formaldehyde in PBS. Samples for 
biochemical assays were harvested after 7, 14, 21 and 
28 d, digested overnight at 60 °C in buffer containing 
papain [0.2 M NaH2PO4, 0.01 M EDTA2H2O, 0.01 M 
cysteine HCl, 250 μg/mL papain (Sigma-Aldrich), 
pH 6] and stored at -20 °C until use. Samples for gene 
expression analysis were harvested after 2, 5, 7, 10 and 
14 d of chondrogenic differentiation, homogenised in 
350 μL of TRIzol (Gibco) and stored at -80 °C until use.
Fibrin encapsulation
Pellets and μpellets were collected 24 h post-pelleting 
and suspended in 100 μL of 40 mg/mL human 
fibrinogen, dissolved in 0.9 % NaCl (Sigma-Aldrich) 
at a density of 60 μpellets or 3 standard pellets per 
100 μL of fibrinogen. Human thrombin (Sigma-
Aldrich) was added at a ratio of 0.5 international 
units (IU) to 1 mg of fibrinogen; crosslinking took 
15-20 min. Samples for implantation and in vitro 
analysis were maintained for 7 or 28 d in complete 
chondrogenic medium supplemented with 0.0875 IU/
mL of bovine aprotinin (Sigma-Aldrich), to slow-
down the degradation of the fibrin material caused by 
cell constructs during the in vitro culture. Medim was 
refreshed twice a week and pellets weremainteined 
at 37 °C in 5 % CO2.
Subcutaneous implantation
All experiments were approved by the Animal 
Experiments Committee at the Erasmus Medical 
Centre, Rotterdam, The Netherlands (DEC protocol 
116-12-08). 3 loose pellets, 60 loose μpellets, 3 fibrin-
encapsulated pellets and 60 fibrin-encapsulated 
μpellets (for a total of 600,000 cells per pocket) were 
implanted subcutaneously in 10 (7 d in vitro primed 
samples) or 13 weeks old (28 d in vitro primed 
samples) male athymic nude mice (Balb/c nudes, 
Charles River, Sulzfeld, Germany). Animal were 
housed in groups of three under a standard 12 h light/
dark cycle, with access to food and water ad libitum 
(18 mice in total). Pre-operatively, animals were 
given pain medication (buprenorphine, 0.05 mg/
kg body weight) under general anaesthesia (1-3.5 % 
isoflurane). Two incisions were made dorsally (one 
between the shoulder blades and the other between 
the hip bones), with two subcutaneous pockets 
created per incision. Implantation per pocket 
was performed according to one of the following 
conditions: 3 standard pellets, 3 standard pellets 
encapsulated in fibrin, 60 loose μpellets or 60 μpellets 
encapsulated in fibrin (implantation was randomised 
among pockets and animals). 3 replicates per 
condition and MSC donor (3 MSC donors in total) 
were implanted. 8 weeks post implantation, animals 
were euthanised by CO2 asphyxiation and constructs 
were retrieved.
Micro-computed tomography (µCT) imaging
μCT scans were performed and reconstructed at the 
Applied Molecular Imaging Erasmus MC facility 
using the Quantum FX imaging systems (Perkin-
Elmer, Groningen, The Netherlands). Ex vivo scans 
were acquired using a field of view of 10 mm 
(90 kV/160 mA, 3 min). Scans were quantified using 
the Analyze 11.0 software (AnalyzeDirect, Nieuwe 
Niedorp, The Netherlands). Calcified tissue was 
quantified by converting original linear attenuation 
coefficient measurements, by linear transformation, 
to Hounsfield units (HU). Global thresholding 
was applied to all scans and determined by visual 
inspection. Values over 400 HU, corresponding to 
0.133 g/cm3 (as determined by phantom scans), were 
segmented out and independently quantified as 
calcified tissue.
Histology
Samples were fixed for 2 h (in vitro) or 24 h (in vivo) 
in 4 % (w/v) formaldehyde in PBS. In vivo samples 
were decalcified for 7 to 10 d in 10 % w/v EDTA in 
PBS, changing the solution every other day, then 
embedded in paraffin wax. 6 μm-thick sections were 
cut, deparaffinised and stained with haematoxylin 
Primer 
Name Forward sequence (5’-3’) Reverse sequence (5’-3’)
GAPDH ATGGGGAAGGTGAAGGTCG TAAAAGCAGCCCTGGTGACC
VEGFa CTTGCCTTGCTGCTCTACC CACACAGGATGGCTTGAAG
COLI CAGCCGCTTCACCTACAGC TTTTGTATTCAATCACTGTCTTGCC
COLII CCCCATCTGCCCAACTGA CTCCTTTCTGTCCCTTTGGT
COLX ACTTCTCTTACCACATACACG CCAGGTAGCCCTTGATGATGTACT
BMP2 AACACTGTGCGCAGCTTCC CTCCGGGTTGTTTTCCCAC
MMP13 AAGGAGCATGGCGACTTCT TGGCCCAGGAGGAAAAGC
Table 1. Primer sequences used for real-time PCR. Abbreviations: GAPDH, glyceraldehyde-
3-phosphate dehydrogenase; VEGFa, vascular endothelial growth factor a; COLI, collagen 
type I; COLII, collagen type II; COLX, collagen type X; BMP2, bone morphogenetic protein 
2; MMP13, matrix metallopeptidase 13.
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and eosin (H&E), safranin O or tartrate-resistant acid 
phosphatase (TRAP). 4-5 sections per sample were 
used. H&E staining was performed by incubating 
deparaffinised samples for 5 min in 100 % Gil’s 
haematoxylin (Sigma-Aldrich), followed by 7 min 
incubation in non-distilled water. Next, samples were 
incubated for 45 s in 2 % eosin (Merck, Amsterdam, 
The Netherlands) in 50 % ethanol and 0.5 % acetic acid 
for 10 s in 70 % ethanol, followed by 100 % ethanol 
for 1 min and 100 % xylene for 1 min and mounted 
on coverslips. H&E stained sections were used to 
quantify the percentage of bone, calcified cartilage and 
bone marrow – using morphological characteristics 
to determine boundaries. Aforementioned areas 
were segmented and then quantified using Image 
J software (National Institute of Health; Bethesda, 
MD, USA). Safranin O staining was performed by 
incubating deparaffinised samples for 8 min in 0.05 % 
light green solution (Sigma-Aldrich) in distilled 
water, followed by a rinse in 1 % acetic acid (Fluka, 
Zwijndrecht, The Netherlands) in distilled water 
and a 12 min incubation in 0.1 % safranin O solution 
(Fluka) in distilled water. Subsequently, samples 
were rinsed for 30 s in 96 % ethanol, followed by 
100 % ethanol for 1 min and 100 % xylene for 1 min 
and mounted on coverslips. TRAP staining was 
performed by incubating deparaffinised samples for 
20 min in 0.2 M acetate buffer [0.2 M sodium acetate 
(Sigma-Aldrich), 100 nM L-(+)-tartaric acid (Acros, 
Antwerp, Beligum) pH 5]. Following incubation, 
0.5 mg/mL naphtol AS-BI phosphate (Sigma-Aldrich) 
and 1.1 mg/mL fast red TR salt (Sigma-Aldrich) 
were added to the acetate buffer and incubated 
for 1 h at 37 °C. Collagen type II samples were 
rinsed in distilled water and counterstained with 
haematoxylin, as previously described.
Immunohistochemistry
Samples were prepared as previously described 
(Hellingman et al., 2010). Briefly, collagen type II-
stained samples were incubated for 30 min at 37 °C 
in 1 mg/mL pronase (Sigma-Aldrich) and 10 mg/
mL hyaluronidase (Sigma-Aldrich). 10 % normal 
goat serum (Southern Biotech, Uithoorn, The 
Netherlands) was used to block non-specific antibody 
binding. Sections were incubated with 0.4 mg/mL 
of mouse anti-collagen type II antibody (II-II/II6B3; 
Developmental Studies Hybridoma Bank, University 
of Iowa, Iowa City, IA, USA). Collagen type X staining 
was performed by incubating samples with 0.1 % 
pepsin (Sigma-Aldrich) in 0.5 M acetic acid (pH 2.0), 
followed by 10 mg/mL hyaluronidase treatment. Rat 
knees were decalcified for 2 weeks in 10 % EDTA 
(w/v in distilled water; Sigma-Aldrich). Sections 
were incubated for 16 h with 1 : 10 or 1 : 100 diluted 
mouse anti-collagen type X antibody (X53; Quartett, 
Berlin, Germany; in PBS/1 % BSA). All stainings 
were incubated for 30 min with 2.2 mg/mL of biotin-
SP-AffinityPure F(ab)2 goat anti-mouse antibody 
(Jackson Huissen, The Netherlands) diluted in 
PBS/1 % BSA and washed in PBS. Next, samples were 
incubated for 30 min with streptavidin-AP (Biogenex, 
Uithoorn, The Netherlands) diluted 1 : 50 in PBS/1 % 
BSA and washed in PBS. All slides were incubated 
for 30 min in 0.2 M Tris-HCL substrate (pH 8.5), 
containing 1 g/25 mL Neu Fuchsin (1B467; Fisher 
Scientific, Landsmeer, The Netherlands) in 2 M HCl, 
4 %NaNO2 (Sigma-Aldrich) in distilled water, 0.3 mg/
Fig. 1. Chondrogenic markers were upregulated after 7 d of in vitro priming. (a) Safranin O staining 
(donor 1) and (b) GAG (corrected for DNA) results showed an increase in matrix GAG deposition after 
7 d of culture (all 3 MSC donors, 3 pellets per donor). (c) Expression of ColII and ColX increased after 
7 d of in vitro culture and continued to increase over time (all 3 MSC donors, 3 pellets per donor; graphs 
display mean and standard deviation).
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Fig. 2. Non-encapsulated μpellets failed to differentiate chondrogenically. Safranin O results showed 
that non-encapsulated μpellets exhibited no matrix GAG deposition after 7 or 28 d of culture [(a) donors 
1 and (b) donor 2], whereas other constructs showed positive staining. (c) Donor 3 μpellets aggregated 
forming one pellet after 28 d in culture.
mL Naphtol AS-MX phosphate (Sigma-Aldrich), 
33 μL/mL dimethylformamide (Sigma-Aldrich) and 
0.25 mg/mL levamisole (Sigma-Aldrich). Collagen 
type II samples were rinsed in PBS, followed by 
haematoxylin counterstaining. Matching mouse IgG 
(X0931; Dako, Fisher Scientific) isotype controls were 
performed for each staining.
Biochemical assays
Samples were digested overnight at 60 °C in 
buffer containing papain (as described above). 
Glycosaminoglycan (GAG) content was quantified by 
dimethylmethylene blue (DMB) pH 3 (Sigma-Aldrich) 
assay. Chondroitin sulphate C (Sigma-Aldrich) was 
used to create a standard for this experiment and 
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the absorbance ratio 530 : 590 was used to determine 
the GAG content. DNA was quantified from papain 
digested samples using ethidium bromide with calf 
thymus DNA (Sigma-Aldrich) as a standard.
Gene expression
Samples were homogenised in 350 μL of TRIzol 
(Gibco). 70 μL of 100 % chloroform were added 
and samples were agitated, incubated for 10 min at 
room temperature and then the aqueous phase was 
transferred to RNeasy® micro kit columns (Qiagen, 
Venlo, The Netherlands) for RNA extraction. cDNA 
was reverse transcribed using a First Strand cDNA 
Synthesis Kit (RevertAid, MBI Fermentas, St. 
Leon-Rot, Germany), according to manufactures 
instructions. Real-time PCR was performed using 
10 ng of cDNA. Samples were amplified for a 
maximum of 40 cycles using either SYBR Green I 
dye (Eurogentec, Seraing, Belgium) or TaqMan 2× 
Reagent (Applied Biosystems, Nieuwerkerk a/d, 
Ijssel, The Netherlands) in 10 μL PCR mix reactions 
containing 10 μM forward and reverse primers 
for GAPDH, COLII, COLX, COLI, VEGF, MMP13 
or BMP2 (Table 1). For gene expression analysis, 
3 different MSC donors were analysed with three 
pellets per donor. Gene expression was calculated 
by the 2-ΔΔCt method.
Results
MSCs displayed chondrogenic characteristics 
during the first week of in vitro priming
The effects of in vitro chondrogenic priming time 
were investigated in order to determine the earliest 
stable chondrogenic induction time that could be 
utilised for in vivo bone formation studies. Time 
course experiments, in which MSC pellets were 
differentiated for 2, 5, 7, 10, 14, 21 or 28 d showed 
that GAGs were present early during priming and 
increased greatly by 7 d of in vitro culture, compared 
to earlier time points (Fig. 1a,b). Increased expression 
of chondrogenic genes, including COLII and COLX, 
was observed by 7 d and continued to rise thereafter 
compared to time point 0 (Fig.1c). As chondrogenic 
characteristics were observed to be stably and 
reproducibly increased after 7 d of in vitro priming, 
compared to earlier time points, we chose to continue 
with this time point during in vivo studies.
µpellet-fibrin constructs maintained 
chondrogenic potential compared to standard 
pellets
μpellets were constructed using roughly 10,000 cells 
per μpellet, 20 of these μpellets were equivalent 
to the cell density of our standard pellet, which is 
typically utilised in tissue engineering EO studies. 
μpellets were encapsulated in a 40 mg/mL fibrin gel. 
To ensure fibrin was not inhibiting chondrogenesis, 
the pellets were also encapsulated for comparison. 
Pellets, pellet-fibrin, μpellets and μpellet-fibrin were 
cultured for either 7 or 28 d and then harvested for in 
vitro analysis or subcutaneously implanted in nude 
mice. In vitro, μpellets alone failed to differentiate 
chondrogenically after 7 or 28 d, fibrin encapsulation 
was necessary in order to achieve differentiation 
(Fig. 2). In donor 3, μpellets aggregated following 
prolonged culture (28 d), forming one pellet with 
a decreased chondrogenic potential compared to 
standard pellets cultured from the same donor (Fig 
2c). Safranin O staining suggested a similarity in 
proteoglycan content among pellet, pellet-fibrin 
and μpellet-fibrin constructs after either 7 or 28 d 
of priming, as staining intensity was comparable 
between conditions. Although in earlier primed 
samples it might appear as if the staining of μpellet-
fibrin condition was less intense, the pellets were 
spread over a larger area, distributing the staining 
over the section and the cumulative result was similar 
to that observed in the standard pellet culture. Among 
donors, there was variation in staining intensity 
highlighting a degree of donor variability during 
Fig. 3. μpellet-fibrin constructs maintained cell morphology and exhibited chondrogenic potential. H&E 
staining showing morphology of chondrogenic pellet, pellet-fibrin and μpellet-fibrin (donor 2) was 
comparable among conditions, after 7 and 28 d of differentiation.
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chondrogenesis (Fig. 2). Cell morphology for each 
donor was similar among conditions and time points 
(Fig. 3a). However, after 7 d of culture, GAG/DNA 
data for donor 2 showed that μpellet-fibrin constructs 
contained more GAG compared to pellet counterparts 
(Fig 3b; one donor, 6 replicates). This difference was 
not observed after extended culture (Fig. 3c; one 
donor, 6 replicates).
 Expression of COLII, COLX and COLI was 
observed in all donors after either 7 or 28 d of in 
vitro culture; however, gene expression levels varied 
significantly among donors (Fig. 4). Samples collected 
from donor 1, after both 7 and 28 d of culture, showed 
stronger expression and staining of COLII (Fig. 
4a,5). COLX expression was greater in μpellet-fibrin 
compared to pellets alone, at both 7 and 28 d (Fig. 
4b). Fibrin encapsulation appeared to lead to a more 
intense COLII staining throughout the matrix after 7 
or 28 d of culture, as shown by immunohistochemical 
analysis (Fig. 5). There was no clear variation in COLX 
protein expression among conditions (Fig. 6). In IgG 
control stainings, COLX appeared to  be slightly 
Fig. 4. Matrix components were differentially affected among donors; however, hypertrophic marker 
COLX was consistently upregulated in μpellet-fibrin constructs cultured for 28 d. Expression of (a) 
ColII, (b) ColX and (c) ColI in pellet, pellet-fibrin and μpellet-fibrin constructs after 7 or 28 d of in vitro 
chondrogenic culture. Hypertrophy-associated gene COLX was upregulated in pellet and μpellet-fibrin 
conditions cultured for 28 d.
CA Knuth et al.                                                                                       Micropellet-mediated endochondral ossification
149 www.ecmjournal.org
stained in the fibrin encapsulated material (Fig. 6a). 
This background staining was far less intense than 
the one observed within our constructs. Staining 
specificity was shown in rat knee tissue. However, 
the optimal staining concentration for rat tissue was 
found to be lower than the one observed in human 
(Fig. 6d).
 Generally, μpellet-fibrin conditions had lower 
VEGF gene expression compared to pellet controls 
after 7 d of in vitro culture, an effect that was not 
observed after 28 d of culture (Fig. 7). In donor 1, 
after 28 d of culture, VEGF expression was slightly 
downregulated when compared to donors 2 and 
3 (Fig. 7a). Other secreted factors, including BMP2 
and MMP13, were differentially affected among 
conditions and donors, but were present in all 
samples. Downscaling the standard pellet to μpellet-
fibrin size did not appear to hinder the expression of 
these markers (Fig. 7).
7 d of in vitro chondrogenic priming resulted in 
tissue calcification in vivo
In addition to the in vitro characterisation, pellets, 
pellet-fibrin, μpellets and μpellet-fibrin constructs 
were subcutaneously implanted in nude mice for 8 
weeks and harvested for volumetric and histological 
Fig. 5. μpellet-fibrin constructs exhibited more homogenous collagen type II distribution after longer 
priming. COLII immunohistochemistry on chondrogenically differentiated pellet, pellet-fibrin and μpellet-
fibrin constructs after 7 and 28 d of in vitro culture from MSCs of (a) donor 1, (b) donor 2 and (c) donor 
3.(d) IgG control was performed on donor 1 samples collected at day 28.
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analysis (Fig. 8a). Non-encapsulated μpellets could 
not be located following implantation and thus 
could not be analysed. Between the two in vitro 
priming times, 7 or 28 d, there was significantly more 
calcified tissue present in conditions primed for 28 d 
in vitro, as shown by μCT analysis (Fig. 8b,c). Fibrin 
encapsulation of pellets lead to greater calcification 
in vivo than standard pellets, for all donors’ 
MSCs cultured for 7 d (Fig. 8c). However, fibrin 
encapsulation did not appear to affect calcification 
when constructs were cultured for 28 d. Pellets that 
were not encapsulated in fibrin were only retrieved 
from 1 donor after implantation following 7 d of in 
vitro culture and, for this donor, only 1 pellet of the 
3 implanted was retrieved. Regardless of the donor, 
after in vivo implantation, 7 d primed pellet-fibrin and 
μpellet-fibrin constructs were always retrieved and 
always showed calcification on μCT scans (Fig. 8b,c). 
28 d primed pellets, pellet-fibrin and μpellet-fibrin 
constructs were consistently retrieved from donors 1, 
2 and 3 and always showed comparable calcification 
among donors (Fig. 8b,c). In some donors, as shown 
in the μCT images (Fig. 8), pellets or μpellets merged 
forming one larger construct. This was only observed 
Fig. 6. μpellet-fibrin constructs exhibited more homogenous collagen type X distribution after longer 
priming. COLX immunohistochemistry on chondrogenically differentiated pellet, pellet-fibrin and 
μpellet-fibrin constructs after 7 and 28 d of in vitro culture from (a) donor 1, (b) donor 2 and (c) donor 
3. (d) IgG control was performed on donor 1 samples collected at day 28. (e) Rat knee positive control 
at 1 : 10 and 1 : 100 dilutions.
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within some of the fibrin-encapsulated samples and it 
was not observed consistently with a specific donor, 
priming time or condition.
Bone formation in vivo was dependent on 
extracellular matrix quality pre-implantation
Bone and calcified cartilage were observed in all 
harvested samples. Calcified tissue was quantified 
by μCT (Fig. 9,10). However, non-encapsulated 
pellets primed in vitro for 7 d could only be retrieved 
from donor 1 and the quantity of bone and calcified 
cartilage observed at the time of harvest in H&E 
sections varied among donors. Donor 1 had a 
denser GAG-rich matrix pre-implantation and 
higher COLII and COLX expression/production 
(Fig. 2,4,5,6). After 8 weeks in vivo, it resulted in an 
almost complete absence of bone marrow and only a 
small recruitment of matrix-remodelling osteoclasts 
(Fig. 9-11), compared to donor 2 and 3 that had a less 
GAG-rich matrix pre-implantation and lower COLII 
Fig. 7. Gene expression of secreted factors was differentially affected across donors and maintained in 
μpellet-fibrin constructs. Expression of (a) VEGF, (b) MMP13 and (c) BMP-2 in pellet, pellet-fibrin and 
μpellet-fibrin constructs after 7 or 28 d of in vitro chondrogenic culture. Hypertrophy-associated gene 
BMP2 was upregulated in pellet and μpellet-fibrin conditions in some donors, whereas it was relatively 
unaffected in others. Other markers were differentially affected depending on the donor.
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Fig. 8. 7 d primed samples and μpellet constructs formed mineralised tissue after in vivo implantation. 
(a) In vivo study outline, (b) μCT scans of constructs primed in vitro for 7 or 28 d after 8 weeks of in vivo 
implantation. (MSC from donor 1; the white bar represented an arbitrary length, for comparison among 
μCT images). (c) Volume of mineralised tissue obtained from ex vivo μCT scans showed donor-related 
differences in mineralisation.
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and COLX expression/production (Fig. 2,4,5,6). This 
resulted in a higher percentage of bone marrow 
elements and greater osteoclast recruitment, after 
implantation in vivo for a comparable time (Fig. 
9,10,12,13). These differences were observed most 
clearly in the histological sections, because it was not 
possible, in the μCT, to distinguish between calcified 
cartilage from bone.
Discussion
Priming time and reproducible bone formation 
represent two of the major hurdles for translation of 
TE based approaches to the clinic. In this manuscript, 
we demonstrated that 7 d of chondrogenic priming 
coupled with encapsulation in a fibrin-gel was 
sufficient to allow bone formation in vivo. Following 
7 d of in vitro priming, pellets consistently produced 
a more chondrogenic GAG-rich matrix and 
hypertrophic markers were consistently upregulated. 
However, without encapsulation, only MSCs from 
one donor were observed to calcify in vivo after being 
primed for 7 d in vitro. The same MSCs produced 
no bone marrow elements. Given the lack of bone 
formation, the chondrogenic markers we chose were 
most likely insufficient predictors of in vivo bone 
formation.
 Novel μpellet-fibrin constructs were created 
and characterised to ensure that downscaling the 
standard pellet culture to a μpellet format would 
not inhibit chondrogenesis and subsequent bone 
formation. We observed that μpellet-fibrin constructs 
showed equivalent matrix production and bone 
formation compared to standard pellet culture 
counterparts. In a recent predictive model, it is shown 
Fig. 9. Quantity of bone and bone marrow following 7 d of in vitro priming was donor-dependent. 
Percentage of bone, bone marrow, calcified cartilage and other tissue found in samples primed in vitro for 
7 d following 8 weeks in vivo. Quantification of (a) pellets, (b) pellet-fibrin and (c) μpellet-fibrin (3 constructs 
per condition and donor; 3 MSC donors used) was completed using ImageJ and high magnification (200×) 
images of H&E staining and segmenting areas, based on morphology.
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that matrix deposition and collagen distribution 
tend to accumulate around the outer periphery of 
pellets, where nutrient supply is abundant (Lewis et 
al., 2016). They predicted that uniform distribution 
of proteoglycans and collagens could be maintained 
by decreasing pellet size, which would make 
nutrients and factors more available to individual 
differentiating cells. Indeed, this could explain why 
we saw an increase in some matrix-related genes in 
μpellet constructs. In addition, decreased VEGF gene 
expression in μpellet-fibrin constructs, compared to 
standard pellets, was observed after 7 d of culture, 
but this decrease was not observed after 28 d of in 
vitro priming and did not appear to hinder in vivo 
bone forming capacity in μpellet-fibrin constructs.
 In vivo results confirmed that bone formation 
could be achieved by chondrogenically priming 
constructs for only 7 d in vitro using either standard or 
μpellet-fibrin constructs. Non-encapsulated μpellet 
constructs failed to differentiate in all donors and time 
points, except for non-encapsulated μpellets from 
donor 3 cultured for 28 d. These non-encapsulated 
μpellets aggregated, forming one pellet after 28 d 
of culture. This aggregated pellet and all other non-
encapsulated μpellets that were implanted did not 
result in bone formation, indicating that μpellets 
alone and aggregated μpellets were not capable of 
bone formation. It appeared that μpellets required 
encapsulation, during in vitro differentiation or 
during implantation, in order for bone formation to 
be achieved. We observed that fibrin encapsulation 
increased bone formation when priming time was 
reduced to 7 d in subcutaneously implanted pellet 
constructs. 7 d non-fibrin-encapsulated pellets 
were rarely retrieved (one in three donors) and all 
retrieved pellets lacked bone marrow elements. Given 
the lack of bone formation, it is probable that other 
chondrogenic markers may more accurately predict 
Fig. 10. Quantity of bone and bone marrow following 28 d of in vitro priming was donor-dependent. 
Percentage of bone, bone marrow, calcified cartilage and other tissue found in samples primed in vitro 
for 28 d following 8 weeks in vivo. Quantification of (a) pellets, (b) pellet-fibrin and (c) μpellet-fibrin 
(3 constructs per condition and donor; 3 MSC donors used) was completed using ImageJ and high 
magnification (200×) images of H&E staining and segmenting areas, based on morphology.
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in vivo bone formation than the ones we selected. It 
is possible that pellets that did not calcify or form 
bone were simply absorbed by the host or, perhaps, 
the addition of fibrin prevented this absorption long 
enough for remodelling and bone formation to take 
place.
 Often, fibrin-encapsulated samples exhibited 
fusion in vivo, resulting – in the μCT scans – in a 
fused mass of pellets/μpellets when compared to 
individual non-encapsulated pellets. This fusion 
was not consistently observed among conditions or 
donors, but was only observed in fibrin-encapsulated 
conditions. It could be that the fibrin contracted 
bringing the pellets in closer proximity and allowing 
for this fusion to take place. Fibrin has been shown 
to reduce oxygen diffusion and tension, leading 
to a hypoxic environment (Demol et al., 2011). 
This hypoxic environment is favourable for bone 
formation and has been shown to increase osteoclast 
and osteoblast activity. This may explain how fibrin 
is able to enhance bone formation in vivo (Arnett et 
al., 2003; Hung et al., 2012; Steinbrech et al., 1999). 
However, in a prior pilot study, pellets primed in 
vitro for 7 d in the absence of fibrin did form bone 
containing mature marrow cavities (data not shown). 
This highlights a degree of variability in graft 
performance based on inherent donor differences, 
which have been previously reported (Amini et al., 
Fig.11. High GAG density in vitro resulted in slower remodelling and bone formation in vivo. (a) Day 7 
and (b) day 28 in vivo H&E and TRAP stainings of donor 1. The intensity of the safranin O staining (Fig. 
2) showed that the quantity of GAGs was high pre-implantation. Denser GAG-rich matrices appeared 
to be harder for cells to penetrate, as evident by a decrease in bone marrow formation and osteoclast 
infiltration (in H&E stains CC = calcified cartilage, BM = bone marrow, B = bone; in TRAP staining arrows 
indicate areas of TRAP positivity).
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2012; van der Stok et al., 2014). Indeed, in this study 
we observed that major differences among donors 
influenced the degree of bone formation observed 
following implantation.
 In our study, we observed a difference in 
chondrogenic differentiation and subsequent bone 
formation among all three donors. Samples retrieved 
from donor 1 often lacked bone marrow elements 
following implantation. In vitro analysis from donor 
1 showed a decrease in both VEGF and COLX gene 
expression compared to the other two donors. 
VEGF is known to be involved in vascularisation 
(Yang et al., 2012), which means that this decreased 
expression of VEGF could be attributed to the lack 
of bone marrow elements we observed following 
in vivo implantation. Additionally, donor 1 showed 
greater COLII expression and GAG accumulation, as 
well as, decreased COLX gene expression compared 
to donors 2 and 3. Histologically, we observed 
that GAG and other matrix collagens production 
pre-implantation appeared to be related to bone 
formation in vivo. A denser matrix, containing 
more collagen elements and GAGs, resulted in less 
mature bone formation, more incomplete remodelled 
Fig. 12. GAG density in vitro affected the rate of remodelling and bone formation in vivo. (a) Day 7 and 
(b) day 28 in vivo H&E and TRAP stainings of donor 2. The intensity of the safranin O staining (Fig. 2) 
showed a moderate quantity of GAGs pre-implantation. In vivo there was a varying degree of calcification, 
bone marrow space development and osteoclast infiltration, which appeared to be correlated to in vitro 
GAG deposition pre-implantation (in H&E stains CC = calcified cartilage, BM = bone marrow, B = bone; 
in TRAP staining arrows indicate areas of TRAP positivity).
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calcified cartilage and a decrease in the presence of 
matrix remodelling osteoclasts. These differences 
were best observed in the H&E stained sections, as the 
μCT – quantifying the entire area of calcified tissues 
– were unable to distinguish between quantities of 
bone and calcified cartilage. We hypothesised that 
denser matrices took longer to be remodelled in 
vivo, as vessel and cell invasion were more difficult 
in a dense environment, which resulted in delayed 
bone formation. On the contrary, a less dense matrix 
could be invaded more easily, leading to faster 
vascularisation and remodelling, thus resulting in 
quicker bone formation. Supporting our hypothesis, 
it has previously been shown that GAG depletion in 
articular cartilage leads to an increase in blood vessel 
invasion, which contributes to osteoarthritis and 
bone development in diseased cartilage (Akkiraju 
and Nohe, 2015; Connelly et al., 2008). However, we 
also hypothesised that a minimum level of matrix 
production was necessary for bone formation to 
occur and to prevent pellets from being resorbed 
or lost in vivo, as evidenced by the fact that 7 d 
primed pellets – that had extremely low levels of 
GAG production pre-implantation – were unable to 
Fig. 13. Lower GAG density in vitro resulted in accelerated remodelling and bone formation in vivo. (a) Day 
7 and (b) day 28 in vivo H&E and TRAP staining for donor 3. The intensity of the safranin O staining (Fig. 
2) showed that the quantity of GAGs was low pre-implantation. Less dense GAG-rich matrices appeared 
to be easier for cells to penetrate, as evident by an increased in bone marrow formation and osteoclast 
infiltration (in H&E stains CC = calcified cartilage, BM = bone marrow, B = bone; in TRAP staining arrows 
indicate areas of TRAP positivity).
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be retrieved (donor 2 and 3). It is difficult to say if 
variation in matrix elements alone could justify the 
difference we observed in bone formation. In order 
to properly investigate this aspect, a larger number 
of donors – which we had not access to – needs to be 
investigated in future studies.
 It is also possible that the model we used could 
have hindered or slowed matrix remodelling of more 
dense matrices, such as T-lymphocytes, known to 
degrade GAGs in vivo (Savion et al., 1984), were absent 
from our model. If these T-lymphocytes had been 
present, faster bone formation from samples with 
a more GAG-rich matrix may have been observed. 
However, this would require an immunocompetent 
model in order to be verified. We have used 
immunocompromised mice, lacking functioning 
T- and B-cells, a model which is often employed in 
ectopic bone formation studies (Jukes et al., 2008; Scotti 
et al., 2013). Our group has previously shown that it 
is possible to take chondrogenically primed MSCs 
from rats and implant them into immunocompetent 
animals to achieve bone formation (Farrell et al., 
2011). Whether human MSCs would form bone in an 
immunocompetent animal has yet to be determined. 
As we implanted human MSC pellets in a mouse 
environment, we utilised an immunodeficient mouse 
model to avoid xenographic rejection. Because this 
study was a proof of principle study to characterise 
and determine the de novo bone forming potential 
of the μpellet-fibrin constructs, we implanted our 
constructs in a subcutaneous environment – which 
we felt gave the best conditions to answer our 
question. We chose this instead of a large bone 
defect model, as we were better able to adhere to 
the 3R principle (Kilkenny et al., 2011), i.e. safely 
implanting more conditions per animal allowing for 
fewer animals with minimal discomfort to be used 
to complete the study. Subcutaneous implantation 
of our relatively small constructs did not hinder 
their movement or range of motion. Constructs were 
not in an environment where bone forms naturally 
and this might have limited the bone formation and 
remodelling we observed within our constructs. 
Future studies investigating these constructs in a 
defect environment will be useful.
 μpellet-fibrin constructs were found to have 
equivalent calcification volumes (as assessed by 
μCT) after in vivo implantation, when compared to 
pellets cultured for the same time. These volumes, 
even after 28 d of culture pre-implantion, were still 
far from being sufficient to properly heal a large bone 
defect. As we have not studied how these constructs 
perform in a large defect, we cannot say how they 
would calcify and integrate with the host bone tissue. 
Furthermore, the inherent donor differences we 
observed meant that although samples were primed 
for the same time, the ultimate bone formation varied 
after implantation. This donor variation is an area of 
active research and furthering our understanding 
of what is crucial for endochondral bone formation 
to take place in vivo, in response to certain in vitro 
produced cues, is essential for this research to 
move forward. In addition, there is often a lack of 
bridging between standard pellets, which needs to be 
addressed for proper integration of such constructs 
with host tissue. Scaled-up approaches are still an 
area of active research in this field and in the future 
we hope to investigate these μpellets using bioactive 
injectable matrices in large bone defects to increase 
bone formation. Additionally, understanding the 
relationship between matrix composition pre-
implantation and the subsequent effect on bone 
formation in vivo is important and merits further 
investigation, as determining an optimal set of criteria 
for chondrogenesis pre-implantation to achieve bone 
formation in vivo will improve future research. This 
is also important because identifying such criteria 
would result in more reproducible outcomes, which 
is crucial for the translation of such constructs to the 
clinic. Still we find the bone forming potential of these 
novel μpellet constructs to be promising. We believe 
that, with further optimisation of in vitro culture, we 
could optimise these constructs as an injectable bone 
construct, which would be advantageous to treat 
bone defects.
Conclusions
This study showed that it was possible to decrease 
significantly in vitro culturing for pellet and μpellet 
constructs and still retrieve bone after implantation. 
After further optimisation of culture conditions and 
material parameters, μpellets could offer a promising 
alternative to current clinical treatment options for 
bone defects. Also, we believe that μpellets, due 
to their small size, could be easily optimised as an 
injectable therapy using either a thermoreversible gel 
or injectable fibrin-based material, allowing for the 
creation of a customisable void filling bone substitute. 
Given the shorter priming time required, coupled 
with their injectability, this approach could be a 
promising minimally-invasive therapy for replacing 
some autologous bone transplantation procedures.
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Discussion with Reviewers
Reviwer 1: Based on your results, would there be a 
way to screen donors for their endochondral potential? 
If so, what criteria for initial chondrogenesis do you 
believe would be important after in vitro priming to 
ensure good in vivo results: is it a matrix property, a 
cellular phenotype or both?
Authors: This is a very interesting and relevant 
question. At this point, we cannot state what 
exactly determines ultimate bone formation. We 
observed a less glycosaminoglycan- and collagen-
rich matrix resulting in greater bone formation 
following 28 d of priming. However, as observed in 
our 7 d pellets, there must be a certain quantity of 
glycosaminoglycan and collagen, or a specific level 
of cellular differentiation achieved, in order for bone 
formation to occur. As the cellular phenotype tends 
to dictate the secreted profile of these constructs, it 
is most plausible that this is what controls successful 
bone formation, but what this phenotype is, is not 
clear yet. It should also be noted that, based on many 
recent experiments performed in our lab involving 
subcutaneous implantation, it appears that pellets 
with a very dense matrix take longer to form bone, 
likely due to the requirement for more matrix to be 
broken down and remodelled, but, ultimately, they 
form bone.
Reviewer 1: Based on the premise of developmental 
engineering, one would assume that more 
hypertrophic cartilage, expressing more collagen 
type X and increased proteoglycan deposition, would 
be further along the endochondral pathway and 
therefore convert to bone more quickly. However, 
this is not supported by the results, given that 
systems with less hypertrophy and decreased GAG 
production had better bone formation. Given this, 
what do the authors suggest promoted endochondral 
ossification? Did these constructs go through 
hypertrophic maturation in vivo or are the constructs 
merely osteoconductive?
Authors: Although it is a common assumption that 
hypertrophic differentiation dictates bone formation 
in endochondral constructs, our results showed that 
there were other factors, outside of this controlling 
bone formation, involved. Although the extracellular 
matrix (ECM) is known to play a critical role in bone 
formation, factors produced by MSCs and the cells 
themselves have been shown to be crucial for bone 
formation. The less dense matrix, which allowed for 
a faster cell invasion and quicker matrix remodelling, 
in combination with the secreted factors produced 
by chondrogenically differentiated MSCs, was what 
we believed contributed to the bone formation we 
observed. However, given a longer in vivo period, we 
believe that the pellets with a more GAG-rich, dense 
and Col X-positive matrix would also have formed 
bone. Unpublished data from our group would seem 
to confirm this hypothesis.
Barbero Andrea: The authors speculated that fibrin 
was able to enhance bone formation due to its ability 
to reduce oxygen diffusion and tension. Could the 
authors comment on the possible additional role of 
fibrin in enhancing the recruitment of inflammatory 
cells and/or osteoprogenitors, thus allowing for a 
more efficient remodelling of the cartilage pellets 
in bone?
Authors: Fibrin can recruit monocytic cells, which 
have the potential to further differentiate into 
bone remodelling osteoclasts. This could result in 
accelerated matrix remodelling. Fibrin also supports 
the formation of blood vessels and proliferation 
of mesenchymal stem cells, which would be 
advantageous for bone formation. In order to 
determine if these cells were recruited or their activity 
was enhanced by the presence of fibrin in our study a 
longitudinal in vivo study would be required.
Barbero Andrea: Which specific bone defects are 
envisioned to be treated with the described approach?
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Authors: In future studies, we want to optimise 
these constructs as an injectable bone substitute. As 
injectable, μpellet constructs would be ideal for use 
in non-critical, irregular or more complex-shaped 
bone defects, as they would allow for a tailored 
filling of the void, for example the maxillary sinus, 
or, potentially, for restoring some structure in cases 
of avascular necrosis of the femoral head.
Editor note: The scientific editor for this paper was 
Martin Stoddart.
